Evolving Treatment Landscape in Advanced Renal Cell Carcinoma
Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.
EP: 1.Overview of Advanced RCC and Diagnosis
EP: 2.First-Line Treatment Strategies in Renal Cell Carcinoma
EP: 3.Limitations in Treatment of Metastatic Renal Cell Carcinoma
EP: 4.CheckMate 9ER Trial Updates
EP: 5.CheckMate 9ER: Quality of Life Data and Treatment Implications in Advanced RCC
EP: 6.Triplet Regimens for First-Line Advanced Renal Cell Carcinoma
EP: 7.Clinical Considerations and Treatment Sequencing for Patients with Advanced RCC
EP: 8.Evolving Treatment Landscape in Advanced Renal Cell Carcinoma
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
